Bio-Reference Laboratories Inc (NASDAQ:BRLI) (TREND ANALYSIS) shares were traded with a volume more than five times higher than the usual volume. The stock closed last trading session at $41.93, up by 5.83%, with a volume of 2,473,457 shares against an average volume for the last 3 months of 411,794.
Stock Performance: Click here for a free comprehensive Trend Analysis Report
Bio-Reference Laboratories Inc (NASDAQ:BRLI) stock is currently trading 10.29% below its 52-week-high, 59.31% above its 52-week-low. The 1-year stock price history is in the range of $26.32 – $46.74. Bio-Reference Laboratories Inc (BRLI) has a price to earnings ratio of 23.17 versus Healthcare sector average of 34.12. BRLI stock price has outperformed the Nasdaq by 25.7%. The Medical Labs & Testing Services company is currently valued at $1.16 billion and its share price closed the last trading session at $41.93. The stock has a 50-day moving average of $34.15 and a 200-day moving average of $33.11.
Bio-Reference Laboratories Inc (BRLI) current short interest stands at 4.75 million shares. It has increased by 2% from the same period of last month. Around 20% of the company’s shares, which are float, are short sold. With a 10-days average volume of 2.72 million shares, the number of days required to cover the short positions stand at 1.8 days.
BRLI reported last quarter earnings on June 08. The Medical Labs & Testing Services company announced earnings per share of $0.38 against a consensus Street estimate of $0.46, missing estimate by $0.08. This corresponds to an increase of $0.32 compared to the same quarter of the previous fiscal year.
Is this a Buying Opportunity? Click here for a free Trend Analysis Report
There are currently two analysts that cover Bio-Reference Laboratories Inc stock. Of those two, two have a Hold rating. On a consensus basis this yields to a Hold rating. The consensus target price stands at $38.
In term of ownership, company insiders have had a stable overall shares stock over the last six months while institutions have decreased their positions by 8.72%. As a whole, institutions own 94.1% of the total outstanding shares.
Bio-Reference Laboratories, Inc. operates an independent clinical laboratory in the Northeast United States. The Company’s laboratory has specialty capability in the areas of genomics, oncology, correctional health, and complimentary medicine. Bio-Reference also offers information solutions for reducing healthcare costs and improving quality performance.